{"id":"efv-tdf-ftc","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Neuropsychiatric effects (dizziness, impaired concentration, abnormal dreams)"},{"rate":"10-15","effect":"Rash"},{"rate":"10-15","effect":"Nausea"},{"rate":"5-10","effect":"Diarrhea"},{"rate":"5-10","effect":"Headache"},{"rate":"1-5","effect":"Renal dysfunction (tenofovir-related)"},{"rate":"2-5","effect":"Bone density loss (tenofovir-related)"}]},"_chembl":{"chemblId":"CHEMBL25033","moleculeType":"Small molecule","molecularWeight":"247.25"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"EFV/TDF/FTC combines efavirenz (a non-nucleoside reverse transcriptase inhibitor), tenofovir disoproxil fumarate (a nucleotide reverse transcriptase inhibitor), and emtricitabine (a nucleoside reverse transcriptase inhibitor). Together, these three agents target HIV reverse transcriptase through complementary mechanisms, reducing viral replication and allowing immune reconstitution in HIV-infected patients.","oneSentence":"This is a fixed-dose combination of three antiretroviral agents that work together to inhibit HIV replication through different mechanisms: efavirenz blocks reverse transcriptase, while tenofovir and emtricitabine are nucleotide/nucleoside reverse transcriptase inhibitors.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:10:33.715Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-naïve and treatment-experienced patients"}]},"trialDetails":[{"nctId":"NCT06337032","phase":"PHASE4","title":"A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-08-27","conditions":"HIV-1-infection","enrollment":350},{"nctId":"NCT00042289","phase":"","title":"Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-06-09","conditions":"HIV Infections","enrollment":1578},{"nctId":"NCT02284035","phase":"PHASE3","title":"Safety & Efficacy of Dual Therapy With Raltegravir/Lamivudine","status":"COMPLETED","sponsor":"Juan A. Arnaiz","startDate":"2015-09-27","conditions":"AIDS","enrollment":75},{"nctId":"NCT02285114","phase":"PHASE2, PHASE3","title":"Study To Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in Human Immunodeficiency Virus 1 (HIV-1) Infected Children and Adolescents Virologically Suppressed on a 2-Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (2-NRTI)-Containing Regimen","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-01-20","conditions":"HIV-1","enrollment":41},{"nctId":"NCT02652260","phase":"PHASE2","title":"Effects of Switching From ATRIPLA™ (Efavirenz, Tenofovir, Emtricitabine) to MK-1439A (Doravirine, Tenofovir, Lamivudine) in Virologically-Suppressed Participants (MK-1439A-028)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-03-04","conditions":"HIV-1, Central Nervous System","enrollment":86},{"nctId":"NCT01380080","phase":"PHASE4","title":"REMEMBER: Reducing Early Mortality & Morbidity by Empiric Tuberculosis (TB) Treatment","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2011-10","conditions":"HIV Infection","enrollment":851},{"nctId":"NCT02722421","phase":"PHASE2","title":"Pharmacologic Strategies to Use the Levonorgestrel Implant in HIV-infected Women","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2017-04-06","conditions":"HIV, Contraception","enrollment":28},{"nctId":"NCT06619288","phase":"","title":"Good-first: B/F/TAF As First-line ART","status":"RECRUITING","sponsor":"Affiliated Hospital of Nantong University","startDate":"2024-07-01","conditions":"HIV Infection","enrollment":630},{"nctId":"NCT03502005","phase":"PHASE4","title":"Efficacy, Safety & Tolerability of Switching EFV/TDF/FTC to BIC/FTC/TAF in Virologically Suppressed Adults With HIV-1","status":"COMPLETED","sponsor":"Midland Research Group, Inc.","startDate":"2018-03-01","conditions":"Human Immunodeficiency Virus","enrollment":100},{"nctId":"NCT01789879","phase":"PHASE2","title":"A Pharmacokinetic Evaluation of Levonorgestrel Implant and Antiretroviral Therapy","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2014-03-04","conditions":"HIV, Contraception","enrollment":60},{"nctId":"NCT04433780","phase":"PHASE3","title":"DORA: A Doravirine-based First-line Antiretroviral Therapy for Women of Reproductive Potential Living With HIV","status":"COMPLETED","sponsor":"Professor Francois Venter","startDate":"2021-01-04","conditions":"HIV-1-infection","enrollment":133},{"nctId":"NCT02475915","phase":"PHASE1, PHASE2","title":"Efficacy of VHM After Treatment Interruption in Subjects Initiating ART During Acute HIV Infection","status":"COMPLETED","sponsor":"SEARCH Research Foundation","startDate":"2015-01","conditions":"Acute HIV Infection","enrollment":15},{"nctId":"NCT03916328","phase":"PHASE4","title":"BONE: STAR (Switching to TAF Based Anti-Retroviral Therapy) Study","status":"UNKNOWN","sponsor":"MU-JHU CARE","startDate":"2019-12-03","conditions":"Bone Loss","enrollment":330},{"nctId":"NCT03122262","phase":"PHASE3","title":"ADVANCE Study of DTG + TAF + FTC vs DTG + TDF + FTC and EFV + TDF+FTC in First-line Antiretroviral Therapy","status":"COMPLETED","sponsor":"Professor Francois Venter","startDate":"2017-01-16","conditions":"HIV-1 Infection","enrollment":1110},{"nctId":"NCT04296695","phase":"PHASE4","title":"Biktarvy in Treatment-Naïve Late Presenters With HIV-1 Infection","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2021-07-14","conditions":"HIV-1-infection","enrollment":250},{"nctId":"NCT03048422","phase":"PHASE3","title":"Evaluating the Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their Infants","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-01-19","conditions":"HIV Infections","enrollment":643},{"nctId":"NCT04424264","phase":"PHASE1","title":"The Effect of Rifampicin on the Pharmacokinetics of Intracellular Tenofovir-diphosphate and Tenofovir When Coadministered With Tenofovir Alafenamide Fumarate During the Maintenance Phase of Tuberculosis Treatment in TB/HIV-1 Coinfected Participants","status":"COMPLETED","sponsor":"Professor Francois Venter","startDate":"2019-12-05","conditions":"HIV-1-infection, Tuberculosis","enrollment":18},{"nctId":"NCT00074581","phase":"PHASE3","title":"Preventing Sexual Transmission of HIV With Anti-HIV Drugs","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-02","conditions":"HIV Infections","enrollment":3526},{"nctId":"NCT00039741","phase":"PHASE2, PHASE3","title":"Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2002-08","conditions":"HIV Infections","enrollment":266},{"nctId":"NCT01435018","phase":"PHASE3","title":"Three Chemo Regimens as an Adjunct to ART for Treatment of Advanced AIDS-KS","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2013-10-01","conditions":"HIV-1 Infection","enrollment":334},{"nctId":"NCT03631732","phase":"PHASE3","title":"Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-08-28","conditions":"HIV-1 Infection","enrollment":496},{"nctId":"NCT01147107","phase":"PHASE4","title":"Hepatic Safety of Raltegravir Versus Efavirenz as HIV Therapy for Patients With HIV and HCV Coinfection","status":"COMPLETED","sponsor":"University of Hawaii","startDate":"2014-02","conditions":"Hepatitis C, Chronic, HIV Infection","enrollment":80},{"nctId":"NCT01815736","phase":"PHASE3","title":"Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-03-27","conditions":"HIV, HIV Infections","enrollment":1443},{"nctId":"NCT01709084","phase":"PHASE3","title":"A Clinical Trial Comparing the Efficacy of Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus TDF/FTC/Efavirenz (TDF/FTC/EFV) in Patients With Undetectable Plasma HIV-1 RNA on Current First-line Treatment","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2013-10-02","conditions":"Human Immunodeficiency Virus-type 1 Infection","enrollment":426},{"nctId":"NCT03076359","phase":"NA","title":"Traditional Healers as Adherence Partners for Persons Living With HIV in Rural Mozambique","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2015-06-10","conditions":"HIV/AIDS","enrollment":320},{"nctId":"NCT02616029","phase":"PHASE3","title":"Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-17","conditions":"HIV-1 Infection","enrollment":66},{"nctId":"NCT00752856","phase":"PHASE2","title":"Raltegravir + Lopinavir/Ritonavir Versus Efavirenz + Tenofovir + Emtricitabine in Treatment Naive Patients","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2008-08-26","conditions":"HIV Infections","enrollment":51},{"nctId":"NCT03405194","phase":"NA","title":"Same-Day Treatment With Genvoya vs. EFV/TDF/3TC","status":"WITHDRAWN","sponsor":"Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic","startDate":"2018-05-01","conditions":"HIV/AIDS","enrollment":""},{"nctId":"NCT02121795","phase":"PHASE3","title":"Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-05-06","conditions":"HIV-1 Infection","enrollment":668},{"nctId":"NCT02616783","phase":"PHASE3","title":"Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-22","conditions":"HIV-1 Infection","enrollment":167},{"nctId":"NCT01011413","phase":"PHASE3","title":"Safety and Efficacy of Reduced Versus Standard Dose Efavirenz (EFV) Plus Two Nucleotides in Antiretroviral-naïve Adults.","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2011-08","conditions":"HIV Infections","enrollment":636},{"nctId":"NCT03595709","phase":"PHASE3","title":"Therapeutic Drug Monitoring Study of Reduced-Dose Efavirenz (400 mg) in Combo Tablet for Patients Receiving Atripla With Viral Suppression in Taiwan","status":"COMPLETED","sponsor":"Yu-Jay Corp.","startDate":"2018-12-06","conditions":"HIV Infections","enrollment":50},{"nctId":"NCT02345226","phase":"PHASE3","title":"Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-01-26","conditions":"HIV-1 Infection","enrollment":881},{"nctId":"NCT01352117","phase":"PHASE3","title":"Antiretroviral Therapy (ART) Alone or With Delayed Chemo Versus ART With Immediate Chemo for Limited AIDS-related Kaposi's Sarcoma","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2011-11-18","conditions":"HIV-1 Infection, Kaposi's Sarcoma","enrollment":192},{"nctId":"NCT02469246","phase":"PHASE3","title":"Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-06-29","conditions":"HIV-1 Infection","enrollment":567},{"nctId":"NCT00335322","phase":"PHASE4","title":"ALTAIR - Alternative Antiretroviral Strategies : a Comparison of Three Initial Regimens","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2007-02","conditions":"Human Immunodeficiency Virus (HIV)","enrollment":329},{"nctId":"NCT01632891","phase":"PHASE1, PHASE2","title":"Comparing PI-Based to a nNRTI-based ART for Clearance of Plasmodium Falciparum Parasitemia in HIV-Infected","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2014-01-10","conditions":"HIV-1 Infection, Pf Subclinical Parasitemia","enrollment":52},{"nctId":"NCT01529749","phase":"PHASE4","title":"Effects of Losartan and Antiretroviral Regimen Containing Raltegravir in Fibrosis Inflammation Mediators, Cardiovascular Risk and Neurocognitive Disorders in HIV Infected Patients Previously Effectively Treated","status":"COMPLETED","sponsor":"Felipe Garcia","startDate":"2012-02","conditions":"HIV-1 Infection","enrollment":48},{"nctId":"NCT03251690","phase":"NA","title":"Switching TDF/FTC/EFV to TDF/FTC/RPV VS Continuing TDF/FTC/EFV in HIV Patients With Complete Virological Suppression","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2016-10-27","conditions":"Anti-Retroviral Agents, Efavirenz, HIV-1-infection","enrollment":246},{"nctId":"NCT02605954","phase":"PHASE3","title":"Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-18","conditions":"HIV-1 Infection","enrollment":275},{"nctId":"NCT00442962","phase":"PHASE4","title":"HIV Treatment Reinitiation in Women Who Received Anti-HIV Drugs to Prevent Mother-to-Child Transmission of HIV","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2007-05","conditions":"HIV Infections","enrollment":54},{"nctId":"NCT01403051","phase":"PHASE2","title":"High Dose Vitamin D and Calcium for Bone Health in Individuals Initiating HAART","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2011-09","conditions":"HIV-1 Infection","enrollment":167},{"nctId":"NCT00118898","phase":"PHASE3","title":"Efavirenz or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir Disoproxil Fumarate or Abacavir/Lamivudine in HIV Infected Treatment-Naive Adults","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2005-09","conditions":"HIV Infections","enrollment":1864},{"nctId":"NCT00108862","phase":"PHASE4","title":"Immediate Versus Deferred Start of Anti-HIV Therapy in HIV-Infected Adults Being Treated for Tuberculosis","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2006-08","conditions":"HIV Infection, Tuberculosis","enrollment":809},{"nctId":"NCT00084136","phase":"PHASE4","title":"Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2005-05","conditions":"HIV Infections","enrollment":1571},{"nctId":"NCT02415595","phase":"PHASE2","title":"Dose-finding Study of BMS-955176 to Treat HIV-1 Infected Treatment-naive Adults","status":"TERMINATED","sponsor":"ViiV Healthcare","startDate":"2015-05-12","conditions":"Infection, Human Immunodeficiency Virus","enrollment":210},{"nctId":"NCT02042001","phase":"PHASE4","title":"Switching From Efavirenz/Atripla to Rilpivirine Among Patients With Neurocognitive or Neuropsychological Side Effects","status":"COMPLETED","sponsor":"Azienda Ospedaliera San Gerardo di Monza","startDate":"2015-07-01","conditions":"Impaired Cognition, Depression/Anxiety, Poor Quality Sleep","enrollment":74},{"nctId":"NCT01891799","phase":"","title":"Swaziland Safe Generations","status":"COMPLETED","sponsor":"Columbia University","startDate":"2013-08","conditions":"HIV/AIDS","enrollment":2518},{"nctId":"NCT01935830","phase":"EARLY_PHASE1","title":"LAAM-HAART PET Imaging","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2013-08","conditions":"Healthy Volunteers","enrollment":10},{"nctId":"NCT02499874","phase":"PHASE1","title":"SSAT063- Pharmacokinetics of Efavirenz 400 mg Once Daily During Pregnancy in HIV-1 Infected Women","status":"COMPLETED","sponsor":"St Stephens Aids Trust","startDate":"2015-08","conditions":"HIV","enrollment":26},{"nctId":"NCT01978743","phase":"NA","title":"Advanced Neuroimaging Evaluation of CNS Changes Associated With Efavirenz Therapy Switch to an Raltegravir-based Regimen","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2014-01","conditions":"HIV, HIV-associated Neurocognitive Disorder, Neurotoxicity","enrollment":10},{"nctId":"NCT01516970","phase":"PHASE3","title":"Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)","status":"COMPLETED","sponsor":"Janssen-Cilag G.m.b.H","startDate":"2011-11-25","conditions":"Human Immunodeficiency Virus (HIV)","enrollment":312},{"nctId":"NCT02832778","phase":"PHASE1","title":"Pharmacokinetics of Efavirenz in the Presence of Rifampicin and Isoniazid","status":"UNKNOWN","sponsor":"St Stephens Aids Trust","startDate":"2016-11-21","conditions":"HIV","enrollment":35},{"nctId":"NCT00369941","phase":"PHASE3","title":"A Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus Efavirenz in Treatment Naive HIV-Infected Patients, Each in Combination With TRUVADA (0518-021 EXT)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-08","conditions":"HIV Infections","enrollment":566},{"nctId":"NCT01040091","phase":"PHASE1","title":"Evaluation of the Cellular Pharmacology of Tenofovir and Emtricitabine According to HIV Infection Status","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2009-12","conditions":"HIV Infections","enrollment":34},{"nctId":"NCT01509508","phase":"NA","title":"Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2012-03","conditions":"HIV Infection","enrollment":28153},{"nctId":"NCT02827643","phase":"NA","title":"Vitamin D and Calcium Supplement Attenuate Bone Loss Among HIV- Infected Patients Receiving Tenofovir Disoproxil Fumarate, Lamivudine or Emtricitabine and Efavirenz","status":"UNKNOWN","sponsor":"Mahidol University","startDate":"2016-06","conditions":"Bone Density","enrollment":48},{"nctId":"NCT01479634","phase":"NA","title":"Early HIV Therapy in Patients With High CD4 Cell Counts","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2011-10","conditions":"HIV","enrollment":279},{"nctId":"NCT00476463","phase":"PHASE2","title":"Efficacy of Tenofovir and Emtricitabine in ARV-naive Patients With HIV/HBV Co-infection","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2005-04","conditions":"Hepatitis B Virus, HIV Infections","enrollment":24},{"nctId":"NCT01515813","phase":"PHASE2","title":"Effect of HAART Vs. Statin Treatment on Endothelial Function and Inflammation/Coagulation","status":"WITHDRAWN","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2011-11","conditions":"HIV-1 Infection","enrollment":""},{"nctId":"NCT01495702","phase":"PHASE3","title":"Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2011-12","conditions":"Acquired Immunodeficiency Syndrome, HIV Infections","enrollment":439},{"nctId":"NCT01095796","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2010-03","conditions":"HIV, HIV Infections","enrollment":707},{"nctId":"NCT00863668","phase":"NA","title":"Raltegravir Activity In Lymphoid Tissues","status":"WITHDRAWN","sponsor":"University of Minnesota","startDate":"2009-03","conditions":"HIV Infection, HIV Infections","enrollment":""},{"nctId":"NCT01474954","phase":"","title":"Investigation of The Effect of Cenicriviroc (CVC) Plus FTC/TDF on Cardiovascular Disease Risk Factors","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2011-09","conditions":"HIV Infection","enrollment":5},{"nctId":"NCT01583439","phase":"NA","title":"The Mochudi Prevention Project ART Protocol","status":"TERMINATED","sponsor":"Harvard School of Public Health (HSPH)","startDate":"2012-09","conditions":"HIV Infections","enrollment":11},{"nctId":"NCT01309243","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2011-02","conditions":"HIV-1 Infection","enrollment":799},{"nctId":"NCT01180075","phase":"","title":"Tenofovir, Emtricitabine, Efavirenz and Atazanavir Pharmacokinetics in the Aging HIV-Infected Population","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2010-05","conditions":"Human Immunodeficiency Virus","enrollment":85},{"nctId":"NCT01565889","phase":"PHASE1, PHASE2","title":"Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients.","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2012-03","conditions":"Hepatitis C, HIV","enrollment":52},{"nctId":"NCT00978237","phase":"PHASE4","title":"Clinical Trial to Assess the Effect of the Change of Efavirenz (EFV) for Lopinavir/Ritonavir (LPV/r) in Lipoatrophy in HIV-infected Patients","status":"COMPLETED","sponsor":"Juan A. Arnaiz","startDate":"2009-10","conditions":"HIV Infections, Lipoatrophy","enrollment":20},{"nctId":"NCT00444379","phase":"PHASE4","title":"Anti-Retrovirals for Kaposi's Sarcoma","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2007-04","conditions":"Kaposi's Sarcoma, HIV Infections","enrollment":224},{"nctId":"NCT01254656","phase":"PHASE2","title":"A Long Term Safety Study Of Lersivirine For The Treatment Of HIV-1 Infection In Subjects Who Have Completed Treatment With Lersivirine In Studies A5271015 And A5271022","status":"TERMINATED","sponsor":"Pfizer","startDate":"2011-02","conditions":"HIV-1","enrollment":108},{"nctId":"NCT00869557","phase":"PHASE2","title":"Study of the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2009-04","conditions":"HIV, HIV Infections","enrollment":71},{"nctId":"NCT00624195","phase":"PHASE2, PHASE3","title":"Clinical Trial of CNS-targeted HAART (CIT2)","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2007-03","conditions":"HIV Infections","enrollment":59},{"nctId":"NCT00824421","phase":"PHASE2","title":"A Study Of Different Doses Of UK-453, 061 Plus Truvada Compared To Efavirenz Plus Truvada In Patients Who Have Not Been Previously Treated For HIV-1","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-02","conditions":"HIV-1","enrollment":195},{"nctId":"NCT01270802","phase":"PHASE4","title":"Effects of Switching Efavirenz to Raltegravir on Vascular Function and Bone Markers in HIV-infected Patients","status":"COMPLETED","sponsor":"Indiana University","startDate":"2011-04","conditions":"HIV","enrollment":30},{"nctId":"NCT01541085","phase":"","title":"An Immunologic Study of Treatment-Naive HIV Patients Starting a Darunavir/Ritonavir- or Efavirenz-Based HAART","status":"COMPLETED","sponsor":"Janssen-Cilag S.p.A.","startDate":"2011-12","conditions":"Human Immunodeficiency Virus; HIV","enrollment":33},{"nctId":"NCT01516060","phase":"PHASE3","title":"The Neurocognitive Sub-study of Encore1","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2012-01","conditions":"HIV","enrollment":71},{"nctId":"NCT00799136","phase":"PHASE2","title":"A Feasibility Study of Co-administering Combination Antiretroviral Therapy (cART) and R-EPOCH Chemotherapy for the Management of ARL","status":"COMPLETED","sponsor":"Ontario Clinical Oncology Group (OCOG)","startDate":"2008-02","conditions":"Lymphoma, AIDS Related, HIV Infections","enrollment":6},{"nctId":"NCT01338883","phase":"PHASE2","title":"Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus","status":"COMPLETED","sponsor":"Tobira Therapeutics, Inc.","startDate":"2011-06","conditions":"HIV-1 Infection","enrollment":143},{"nctId":"NCT00302822","phase":"PHASE3","title":"Intensification With Enfuvirtide in Naive HIV-infected Patients (ANRS130)","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2006-04","conditions":"HIV Infections, AIDS","enrollment":195},{"nctId":"NCT01451333","phase":"PHASE3","title":"The Efavirenz (EFV) Central Nervous System Exposure Sub-study of Encore1","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2011-09","conditions":"HIV Infection","enrollment":32},{"nctId":"NCT01271894","phase":"PHASE3","title":"The Intensive Pharmacokinetics Sub-study of Encore1 (ENCORE1-PK)","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2011-09","conditions":"HIV Infection","enrollment":40},{"nctId":"NCT01286740","phase":"PHASE2","title":"Study to Evaluate Switching From a Regimen Consisting of the Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (STR) to the Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate STR","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2011-01","conditions":"HIV-1 Infection","enrollment":50},{"nctId":"NCT00759070","phase":"PHASE4","title":"Effects of 2 Initial Standard Antiretroviral Combinations Therapies on Lipid Metabolism","status":"UNKNOWN","sponsor":"Juan A. Arnaiz","startDate":"2008-09","conditions":"HIV Infections","enrollment":50},{"nctId":"NCT01159743","phase":"","title":"A Comparison of Body Fat Distribution in HIV-1 Infected Patients Receiving, Since the Beginning and for at Least Two Years, an Antiretroviral Therapy Based on Efavirenz or Lopinavir/Ritonavir Combined With Tenofovir + Emtricitabine or Lamivudine","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2010-07","conditions":"HIV Infection","enrollment":346},{"nctId":"NCT00988780","phase":"NA","title":"Maraviroc (CCR5) Antagonism to Decrease the Incidence of the Immune Reconstitution Inflammatory Syndrome in HIV-Infected Patients","status":"UNKNOWN","sponsor":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","startDate":"2009-12","conditions":"Immune Reconstitution Inflammatory Syndrome, HIV, HIV Infections","enrollment":276},{"nctId":"NCT00454337","phase":"PHASE3","title":"Efficacy and Tolerance of the Switch From Enfuvirtine to Raltegravir in Antiretroviral Therapy Regimen in HIV Patients With Undetectable Viral Load","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2007-05","conditions":"HIV Infections","enrollment":170},{"nctId":"NCT00666055","phase":"","title":"Sex, Aging and Antiretroviral Pharmacokinetics","status":"COMPLETED","sponsor":"Kristine Patterson, MD","startDate":"2008-03","conditions":"HIV Infections","enrollment":11},{"nctId":"NCT00936195","phase":"PHASE3","title":"Universal Use of EFV-TDF-FTC and AZT-3TC-LPV/r Combinations for HIV-1 PMTCT in Pregnant and Breastfeeding Women : a Phase 3 Trial","status":"WITHDRAWN","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2010-01","conditions":"HIV Infection, Pregnancy, Breastfeeding","enrollment":""},{"nctId":"NCT00115609","phase":"PHASE3","title":"Efficacy of Tenofovir-Emtricitabine and Efavirenz in HIV Infected Patients With Tuberculosis (ANRS129)","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2006-01","conditions":"HIV Infections, Tuberculosis","enrollment":70},{"nctId":"NCT00615745","phase":"PHASE4","title":"ONCE - Only Nocturnal Combination Evaluation of Antiretroviral-Experienced HIV 1 Infected Subjects Switching to Atripla","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2008-04","conditions":"HIV Infections","enrollment":115},{"nctId":"NCT00549198","phase":"PHASE4","title":"KIVEXA Vs TRUVADA, Both Administered With Efavirenz, In ART-Naive Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-06","conditions":"Infection, Human Immunodeficiency Virus I, HIV Infection","enrollment":392},{"nctId":"NCT01108926","phase":"PHASE1","title":"PK of Tenofovir, Emtricitabine and Efavirenz in Healthy Volunteers","status":"COMPLETED","sponsor":"St Stephens Aids Trust","startDate":"2010-06","conditions":"HIV Infection, HIV Infections","enrollment":19},{"nctId":"NCT00112047","phase":"PHASE3","title":"Tenofovir Disoproxil Fumarate/Emtricitabine/Efavirenz Versus Combivir/Efavirenz in Antiretroviral-Naive HIV-1 Infected Subjects","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2003-07","conditions":"HIV Infections","enrollment":517},{"nctId":"NCT00615810","phase":"PHASE4","title":"ROCKET I - Randomized Open Label Switch for Cholesterol Elevation on Kivexa Evaluation Trial","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2008-03","conditions":"HIV Infections","enrollment":159},{"nctId":"NCT00990600","phase":"PHASE3","title":"QoL and Adherence to One-pill Once-a-day HAART","status":"COMPLETED","sponsor":"A.O. Ospedale Papa Giovanni XXIII","startDate":"2008-04","conditions":"HIV Infection, HIV Infections","enrollment":212},{"nctId":"NCT00365612","phase":"PHASE4","title":"Single Tablet Regimen (STR) Simplification Study for HIV-1 Infected Patients","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2006-07","conditions":"HIV Infections","enrollment":300},{"nctId":"NCT00158457","phase":"PHASE3","title":"Simple Once Daily Triple Regimen Including Tenofovir, Emtricitabine and Efavirenz in HIV-1 Infected Patients (ANRS 1207)","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2004-06","conditions":"HIV Infection","enrollment":40},{"nctId":"NCT00121017","phase":"PHASE2","title":"A Study Exploring an Induction-Maintenance Kaletra-Based Therapy Versus a Sustiva-Based Regimen in Previously Non-Treated, HIV-1/HCV Co-Infected Subjects","status":"WITHDRAWN","sponsor":"Abbott","startDate":"","conditions":"HIV Infection, Hepatitis C","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["NNRTI-Based Regimen"],"phase":"phase_3","status":"active","brandName":"EFV/TDF/FTC","genericName":"EFV/TDF/FTC","companyName":"Juan A. Arnaiz","companyId":"juan-a-arnaiz","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a fixed-dose combination of three antiretroviral agents that work together to inhibit HIV replication through different mechanisms: efavirenz blocks reverse transcriptase, while tenofovir and emtricitabine are nucleotide/nucleoside reverse transcriptase inhibitors. Used for HIV-1 infection in treatment-naïve and treatment-experienced patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}